Shares of Pfizer Inc. PFE inched 0.11% higher to $26.74 Tuesday, on what proved to be an all-around great trading session for ...

A once-groundbreaking sickle cell disease drug — at the center of a $5.4 billion acquisition two years ago — is the subject ...

We recently published a list of the 8 Best Dividend Leaders to Buy According to Wall Street Analysts. In this article, we are ...

We recently compiled a list of the 13 Best Dividend Stocks to Buy Under $50. In this article, we are going to take a look at ...

On Friday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $26.36 which represents a slight increase of $0.59 or 2.29% from the prior close of $25.77. The stock opened at $ and touched a ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other best stocks to buy and hold for 3 years. On December 12, Tom Lee, Fundstrat Global Advisors ...

We recently published a list of the 10 Best Stocks to Buy and Hold For 3 Years. In this article, we are going to take a look ...

On Thursday, Pfizer Inc (PFE) stock saw a decline, ending the day at $25.77 which represents a decrease of $-0.12 or -0.46% from the prior close of $25.89. The stock opened at $25.7 and touched a low ...

In a report released yesterday, Steve Scala from TD Cowen maintained a Hold rating on Pfizer (PFE – Research Report). The company’s shares ...

Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) in combination ...

Pfizer’s BRAFTOVI combination regimen receives US FDA approval for treatment of metastatic colorectal cancer: New York Monday, December 23, 2024, 10:00 Hrs [IST] Pfizer Inc anno ...